IRMD | Ticker Profile - Titan Protect

IRMD

IRADIMED CORPORATION

Healthcare · Medical Devices · NGM

$93.07

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.2B

Total market value of the company

Trailing P/E

50.19

Expensive — high growth expected

Forward P/E

39.00

Based on estimated future earnings — lower means cheaper

Rev Growth

+12.6%

Year-over-year revenue change

Profit Margin

27.4%

How much profit the company keeps from each dollar of revenue

ROE

25.0%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$118.00

+27% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 2 analysts covering this stock

About IRADIMED CORPORATION

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device. It also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. The company serves hospitals, acute care facilities, and outpatient imaging centers. It sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors in the United States and internationally. The company was incorporated in 1992 and is headquartered in Orlando, Florida.

https://www.iradimed.com

Country: United States Employees: 166 Industry: Medical Devices

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

1.393

Excellent risk-adjusted returns

Kelly Fraction

0.1072

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

2.268

Returns exceed worst-case losses — strong risk profile

Annual Return

50.1%

Historical annualised return based on price data

Max Drawdown

-22.1%

Largest peak-to-trough decline — the worst it has been

HMM State

BULL

Statistical model sees bullish momentum

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.91

Less volatile than the market — more defensive

52W High

$107.90

14% below the year high

52W Low

$53.41

74% above the year low

Avg Volume

106,391

Average daily shares traded — higher means easier to buy and sell

Short Ratio

6.0

Days it would take all short sellers to cover — higher means more crowded

Short % Float

8.0%

Moderate short interest

Div Yield

87.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$1.81

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

7.13

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

5.76

Like current ratio but excludes inventory — stricter test

Gross Margin

76.8%

Revenue left after cost of goods — higher means pricing power

Operating Margin

32.9%

Profit from core operations before interest and tax

Free Cash Flow

$15M

Positive — the business generates more cash than it spends

Revenue (TTM)

$86M

Total revenue over the last 12 months

Net Income

$24M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$120.00

Target Median

$118.00

Target Low

$116.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go